ReForm Therapeutics CZ

Noveeda is a biopharmaceutical company developing needle-free drug delivery formulations for life-threatening conditions. Its lead product, Nasefrin, is an intranasal epinephrine formulation for anaphylaxis, and its pipeline includes candidates for poisoning (NVE-02), breakthrough seizures (NVE-03) and hypoglycaemia (NVE-04).

The company describes its target customers as patients and doctors in Central Europe and the Middle East, and says it is building a commercial business to provide novel therapies and diagnostic options to them alongside its product development. The website does not describe a revenue model or any current sales.

Noveeda was founded in 2022 and is registered in Brno, Czechia, where it operates a centre for drug development. Its executive team and research staff are based across the UK, Czechia, Switzerland and Dubai. The website lists the CEO as Rob Chisholm and gives a development timeline through 2029 for its pipeline products.

Product: Nasefrin, an intranasal epinephrine formulation for anaphylaxis, plus pipeline candidates NVE-02, NVE-03 and NVE-04 for poisoning, breakthrough seizures and hypoglycaemia.